The acquisition included purchase of all the shares of the entities through which Banner conducts its operations for a purchase price of nearly $255m, subject to adjustment for working capital and pay-off amounts for existing debt and transaction expenses.
FULL ARTICLE AT Pharmaceutical Industry News